Analysts Offer Insights on Healthcare Companies: Intra-Cellular Therapies (ITCI), Amylyx Pharmaceuticals Inc (AMLX) and Intuitive Surgical (ISRG)
Intra-Cellular Therapies Analyst Ratings
Morgan Stanley Maintains Intra-Cellular Therapies(ITCI.US) With Buy Rating, Raises Target Price to $95
Jefferies Maintains Intra-Cellular Therapies(ITCI.US) With Buy Rating, Maintains Target Price $105
Intra-Cellular Therapies Price Target Maintained With a $130.00/Share by Cantor Fitzgerald
Cantor Fitzgerald Reiterates Overweight on Intra-Cellular Therapies, Maintains $130 Price Target
Stock Moves Reflect Downgrade for US Economic Growth Outlook - Goldman
Intra-Cellular Therapies Raised to Overweight From Neutral by Piper Sandler
Piper Sandler Upgrades Intra-Cellular Therapies(ITCI.US) to Buy Rating, Raises Target Price to $92
Intra-Cellular Therapies Analyst Ratings
JP Morgan Maintains Overweight on Intra-Cellular Therapies, Raises Price Target to $81
J.P. Morgan Maintains Intra-Cellular Therapies(ITCI.US) With Buy Rating, Raises Target Price to $81
CCORF Maintains Intra-Cellular Therapies(ITCI.US) With Buy Rating, Maintains Target Price $113
Intra-Cellular Therapies: A Buy Rating on Strong Commercial Performance and Robust Pipeline
Analysts Offer Insights on Healthcare Companies: EyePoint Pharmaceuticals (EYPT), Sarepta Therapeutics (SRPT) and Intra-Cellular Therapies (ITCI)
Buy Rating Affirmed for Intra-Cellular Therapies Amid Strong Sales and Expansion Potential
RBC Capital Remains a Buy on Intra-Cellular Therapies (ITCI)
Goldman Sachs Maintains Neutral on Intra-Cellular Therapies, Lowers Price Target to $74
RBC Trims Price Target on Intra-Cellular Therapies to $106 From $107, Keeps Outperform Rating
Buy Rating Affirmed for Intra-Cellular Therapies Amidst Strong Q2 Sales and Strategic Growth Initiatives